A new trading day began on Monday, with Moderna Inc (NASDAQ: MRNA) stock price up 0.83% from the previous day of trading, before settling in for the closing price of $27.61. MRNA’s price has ranged from $23.15 to $170.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 662.63% over the last five years. Meanwhile, its annual earnings per share averaged -9.48%. With a float of $341.66 million, this company’s outstanding shares have now reached $387.00 million.
The firm has a total of 5800 workers. Let’s measure their productivity. In terms of profitability, gross margin is 52.55%, operating margin of -118.04%, and the pretax margin is -107.82%.
Moderna Inc (MRNA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 11.45%, while institutional ownership is 67.90%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,004,318. In this transaction Chief Executive Officer of this company bought 160,314 shares at a rate of $31.22, taking the stock ownership to the 9,210,686 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Director bought 31,620 for $31.76, making the entire transaction worth $1,004,251. This insider now owns 312,027 shares in total.
Moderna Inc (MRNA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.72% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Here are Moderna Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.72, a number that is poised to hit -2.98 in the next quarter and is forecasted to reach -7.55 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Analysing the last 5-days average volume posted by the [Moderna Inc, MRNA], we can find that recorded value of 8.64 million was lower than the volume posted last year of 10.93 million. As of the previous 9 days, the stock’s Stochastic %D was 70.31%. Additionally, its Average True Range was 1.75.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 18.20%, which indicates a significant decrease from 84.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.47% in the past 14 days, which was lower than the 77.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.90, while its 200-day Moving Average is $51.33. Now, the first resistance to watch is $28.51. This is followed by the second major resistance level at $29.19. The third major resistance level sits at $29.85. If the price goes on to break the first support level at $27.17, it is likely to go to the next support level at $26.51. Now, if the price goes above the second support level, the third support stands at $25.83.
Moderna Inc (NASDAQ: MRNA) Key Stats
With a market capitalization of 10.77 billion, the company has a total of 386,623K Shares Outstanding. Currently, annual sales are 3,236 M while annual income is -3,561 M. The company’s previous quarter sales were 966,000 K while its latest quarter income was -1,120 M.
